Enveric Biosciences (NASDAQ:ENVB) recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) titled, “Halogenated psilocybin derivatives and methods of using.”

For years, the psychedelic renaissance focused on one clear idea. If you could deliver a guided psychedelic experience safely and predictably, you could lift people out of stubborn depression, trauma, and addiction. That wave brought psilocybin, MDMA, ketamine clinics, and a flood of research interest. However, it was not adoptable by large patient bases.

Focus on prevention and early intervention, especially in youth. Modernize reimbursement models to reward outcomes, not volume. Invest more in innovative therapies that offer rapid, durable symptom relief. Investment is focused on low risk, late stage therapies, but what is needed to really make a difference is the higher risk innovative ideas. Rebuild trust and […]

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and polysomnography) consistent with engagement of neuroplasticity pathways, while delivering rapid and durable antidepressant effects in adults with major depressive disorder (MDD).

Boarded-up mines across the world are rusting symbols of how China seized the world’s critical minerals supply chain. Now, some of these mines—closed not because they ran dry, but by Beijing’s oversupply and price dumping—could be reopened as the Trump administration rallies nations to overthrow China’s supply chain dominance.

Thank you! My journey to founding HLTH Communications wasn’t a straight line. It was more much more like a zigzag that eventually pointed to a clear purpose. I began my career in capital markets, working a boutique investment bank and later working with private as well as public companies raise capital, go public and help […]

The biotech sector has always thrived on storytelling. A compelling narrative can attract capital, energize researchers and capture the public imagination long before a drug makes it to market. But after years of market volatility and overpromises, I’ve noticed many investors are approaching new pitches with sharper scrutiny than ever.

There’s a first time for everything, and now is the time for Enveric Biosciences to submit its first-ever IND to the FDA. After forgoing a Phase 1 in Australia and deciding to out-license that asset, Enveric now finds itself facing its first IND submission. This time, they’re seeking the OK for EB-003, a novel neuroplastogen […]

Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed to be acquired by AbbVie for up to $1.2 billion, Investing.com has learned.

When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been viewed as a fringe pursuit, scientifically intriguing, but clinically and commercially fraught. AbbVie’s decision to pay up for access to Gilgamesh’s pipeline marked a clear […]